AR018304A2 - Acido clavulanico y composicion que lo contiene - Google Patents

Acido clavulanico y composicion que lo contiene

Info

Publication number
AR018304A2
AR018304A2 ARP990100913A ARP990100913A AR018304A2 AR 018304 A2 AR018304 A2 AR 018304A2 AR P990100913 A ARP990100913 A AR P990100913A AR P990100913 A ARP990100913 A AR P990100913A AR 018304 A2 AR018304 A2 AR 018304A2
Authority
AR
Argentina
Prior art keywords
clavulanic acid
composition containing
clavam
production
composition
Prior art date
Application number
ARP990100913A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Univ Alberta filed Critical Smithkline Beecham Plc
Publication of AR018304A2 publication Critical patent/AR018304A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Acido clavulánico que es obtenible por la fermentacion de un microorganismo que tiene facultades para la produccion de 5R-clavam y una produccionbaja o nula de 5S-clavam; y composicion que lo contiene.
ARP990100913A 1997-02-04 1999-03-04 Acido clavulanico y composicion que lo contiene AR018304A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9702218.0A GB9702218D0 (en) 1997-02-04 1997-02-04 Novel product

Publications (1)

Publication Number Publication Date
AR018304A2 true AR018304A2 (es) 2001-11-14

Family

ID=10807030

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980100451A AR011100A1 (es) 1997-02-04 1998-02-02 Adn obtenible de s. clavuligerus, vector que comprende dicho adn, organismo hospedador, s. clavuligerus, procedimiento para mejorar la produccion de5r-clavam en un microorganismo adecuado, microorganismo que tiene las facultades para la produccion de 5r-clavam y una produccion baja o nula de 5s-
ARP990100913A AR018304A2 (es) 1997-02-04 1999-03-04 Acido clavulanico y composicion que lo contiene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980100451A AR011100A1 (es) 1997-02-04 1998-02-02 Adn obtenible de s. clavuligerus, vector que comprende dicho adn, organismo hospedador, s. clavuligerus, procedimiento para mejorar la produccion de5r-clavam en un microorganismo adecuado, microorganismo que tiene las facultades para la produccion de 5r-clavam y una produccion baja o nula de 5s-

Country Status (32)

Country Link
US (5) US6936458B1 (es)
EP (2) EP0970198B1 (es)
JP (2) JP4227199B2 (es)
KR (2) KR100514964B1 (es)
CN (2) CN1696301A (es)
AP (1) AP1320A (es)
AR (2) AR011100A1 (es)
AT (1) ATE312926T1 (es)
AU (1) AU735782B2 (es)
BG (1) BG103704A (es)
BR (1) BR9807144A (es)
CA (1) CA2279207A1 (es)
DE (1) DE69832783T2 (es)
DZ (1) DZ2413A1 (es)
EA (1) EA003773B1 (es)
ES (1) ES2255149T3 (es)
GB (1) GB9702218D0 (es)
HU (1) HUP0001048A3 (es)
ID (1) ID22144A (es)
IL (1) IL131043A0 (es)
MA (1) MA24464A1 (es)
MY (1) MY140928A (es)
NO (1) NO993758D0 (es)
NZ (1) NZ336894A (es)
OA (1) OA11082A (es)
PL (1) PL334961A1 (es)
SK (1) SK105499A3 (es)
TR (1) TR199901862T2 (es)
TW (2) TW589377B (es)
UY (2) UY24874A1 (es)
WO (1) WO1998033896A2 (es)
ZA (1) ZA98868B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019959A1 (en) * 1999-09-16 2001-03-22 The Johns Hopkins University Improvement of clavulanic acid production
EP1228218A2 (en) * 1999-10-22 2002-08-07 Smithkline Beecham Plc 5r clavam producing microorganisms with deleted lat and cvm genes
GB0308696D0 (en) * 2003-04-15 2003-05-21 Glaxo Group Ltd New process
EP2589663A1 (en) 2011-11-04 2013-05-08 LEK Pharmaceuticals d.d. Process for production of clavulanic acid
CN107964522B (zh) * 2018-01-04 2020-12-08 上海交通大学 海洋链霉菌dut11及其抗补体活性应用
KR20220031043A (ko) 2019-07-05 2022-03-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 스트렙토미세스 클라불리게루스

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110165A (en) * 1974-04-20 1978-08-29 Beecham Group Limited Process for the production of clavulanic acid
NL7601227A (nl) * 1975-02-07 1976-08-10 Glaxo Lab Ltd Werkwijze ter bereiding van een nieuw antibioti- cum.
GB1585661A (en) 1976-06-08 1981-03-11 Glaxo Lab Ltd Clavam derivatives
JPS589679B2 (ja) 1977-02-24 1983-02-22 武田薬品工業株式会社 抗生物質の製造法
US4202819A (en) 1979-05-04 1980-05-13 Hoffman-La Roche Inc. 2-(3-Alanyl)clavam antibiotic
GB8521516D0 (en) * 1985-08-29 1985-10-02 Beecham Group Plc Compounds
GB9020683D0 (en) 1990-09-22 1990-11-07 Univ Strathclyde Isolation of dna
CA2108113C (en) * 1993-10-08 2006-12-05 Susan E. Jensen Dna sequence encoding enzymes of clavulanic acid biosynthesis

Also Published As

Publication number Publication date
CN1192107C (zh) 2005-03-09
BR9807144A (pt) 2000-01-25
EP1405913A2 (en) 2004-04-07
ID22144A (id) 1999-09-09
AP1320A (en) 2004-10-29
AU735782B2 (en) 2001-07-12
UY24874A1 (es) 2001-07-31
WO1998033896A2 (en) 1998-08-06
CN1696301A (zh) 2005-11-16
SK105499A3 (en) 2000-05-16
NO993758L (no) 1999-08-03
KR20050053794A (ko) 2005-06-08
TW589377B (en) 2004-06-01
US20030166175A1 (en) 2003-09-04
JP5042186B2 (ja) 2012-10-03
KR20000070723A (ko) 2000-11-25
AP9901614A0 (en) 1999-09-30
ATE312926T1 (de) 2005-12-15
MY140928A (en) 2010-02-12
CA2279207A1 (en) 1998-08-06
DE69832783D1 (de) 2006-01-19
UY25197A1 (es) 1998-11-27
DE69832783T2 (de) 2006-07-20
DZ2413A1 (fr) 2003-01-04
US20030022321A1 (en) 2003-01-30
BG103704A (en) 2000-05-31
EP1405913A3 (en) 2004-08-04
US6936458B1 (en) 2005-08-30
AR011100A1 (es) 2000-08-02
US20070298470A1 (en) 2007-12-27
JP2009022298A (ja) 2009-02-05
JP4227199B2 (ja) 2009-02-18
TR199901862T2 (xx) 2000-12-21
ZA98868B (en) 1999-08-03
EA003773B1 (ru) 2003-08-28
PL334961A1 (en) 2000-03-27
NZ336894A (en) 2001-08-31
EP0970198B1 (en) 2005-12-14
ES2255149T3 (es) 2006-06-16
GB9702218D0 (en) 1997-03-26
WO1998033896A3 (en) 1998-11-19
HUP0001048A2 (hu) 2000-08-28
HUP0001048A3 (en) 2001-09-28
AU6295398A (en) 1998-08-25
TW200307041A (en) 2003-12-01
US20030124690A1 (en) 2003-07-03
NO993758D0 (no) 1999-08-03
OA11082A (en) 2003-03-13
US7344869B2 (en) 2008-03-18
IL131043A0 (en) 2001-01-28
JP2001511001A (ja) 2001-08-07
EP0970198A2 (en) 2000-01-12
CN1251612A (zh) 2000-04-26
MA24464A1 (fr) 1998-10-01
EA199900718A1 (ru) 2000-02-28
KR100514964B1 (ko) 2005-09-15

Similar Documents

Publication Publication Date Title
ES2113652T3 (es) Pamoato de risperidona.
AU5736494A (en) Cyclic sulfone containing retroviral protease inhibitors
ES2055197T3 (es) Una composicion que contiene d-cicloserina y d-alanina para el aumento de la memoria y el aprendizaje o el tratamiento de un trastorno cognitivo o psicotico.
AU1984495A (en) Inhibition of hair growth
ES2196502T3 (es) Composicion y metodo para inhibir el desarrollo de microorganismos que incluye hipobromito sodico estabilizado e isotiazolonas.
FI952797A0 (fi) D-vitamiinianalogin uusi kiteinen muoto
ES2140565T3 (es) Nuevos derivados de pirazina-carboxamida, su preparacion y su utilizacion en medicamentos.
AU5665194A (en) Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
AR018304A2 (es) Acido clavulanico y composicion que lo contiene
ES2159296T3 (es) Procedimiento para preparar 2,2-difluorocetena silil acetales y esteres de acido alfa,alfa-difluoro-beta-sililoxi-1,3-dioxolano-4-propanoico.
AU4765396A (en) Method of preparing retroviral protease inhibitor intermediates
ES2172002T3 (es) Composicion farmaceutica que contiene lornoxicam y una sal disodica del acido etilendiamintetraacetico.
DK0734380T3 (da) 4-Benzoylisoxazoler samt deres anvendelse som herbicider
ES2058141T3 (es) Utilizacion de gamma-glutamil-transpeptidasa.
ES540059A0 (es) Una composicion de conjugado de enzima estabilizado
EP0137301A3 (en) 2-ketocarboxylic-acid reductase, its preparation and its use
ES2144642T3 (es) Proceso de preparacion de la furosemida.
DE69232661D1 (de) Enzymatischer prozess zur herstellung von cefonicid
MX9302878A (es) Procedimiento para la preparacion de un diaminodiol substituido.
FI940334A0 (fi) Pikakuivahiiva
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
ES2146607T3 (es) Mezcla proteolitica que contiene escarasa y metodo de aislar la misma.
ES2093984T3 (es) Procedimiento para la obtencion fermentativa de acido 2-hidroxifenilacetico.
ES2135423T3 (es) Gamma-poliglutamato-hidrolasa y procedimiento de produccion de esta.
ES2087046T1 (es) Resolucion de acido arilalcanoico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure